Abstract
Metabolic syndrome (MS) is a cluster of conditions including abdominal obesity, hypertension, dyslipidemia, and hyperglycemia that are very common in developed countries. The prevalence of MS increases annually. In recent years, a significant increase in the prevalence of MS among young people has been observed. Various markers are currently being studied for their potential to understand this pathology.
Objective: To summarize current understanding of the diagnostic value of biomarkers (including vitamin D, magnesium, and the omega-3 index) and predictive factors (HOMA-IR, TyG, FLI, etc.) in the pathogenesis and clinical management of metabolic syndrome (MS), as well as their relationship with gastrointestinal pathologies such as non-alcoholic fatty liver disease, intestinal microbiota, and chronic inflammation.
Material and methods. A literature review (PubMed, Scopus, eLIBRARY) from 2018 to 2024 was conducted, including original studies, meta-analyses, and clinical guidelines. Levels of vitamin D, magnesium, and the omega-3 index were analyzed, as well as their associations with metabolic syndrome components and associated gastrointestinal disorders.
Keywords
Authors and affiliations
V.I. Bystrova(1, 2), E.V. Shrayner(1, 2),G.I. Lifshits(1, 2), D.A. Kudlay(3–5)
1-Federal State Autonomous Educational Institution of Higher Education “Novosibirsk National Research State University”,
Pirogova str., 1, Novosibirsk, 630090, Russian Federation; 2-Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Avenue, 8, Novosibirsk, 630090, Russian Federation; 3Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health
of the Russian Federation (Sechenov University), Trubetskaya str., 8, build. 2, Moscow, 119991, Russian Federation; 4Federal State Budget Educational Institution of Higher Education M.V. Lomonosov Moscow State University, Leninskie Gory, 1, Moscow, 119991, Russian Federation; 5-The Federal Scientific “State Research Center Institute of Immunology” of the Federal Medical and Biological Agency of Russia, Kashirskoye Shosse, 24, 115522, Moscow, Russian Federation
References
. Moore J.X., Chaudhary N., Akinyemiju T. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis. 2017; 14: E24. Published 2017 Mar 16. doi:10.5888/pcd14.160287
2. Chasens E.R., Imes C.C., Kariuki J.K. et al. Sleep and Metabolic Syndrome. Nurs Clin North Am. 2021; 56 (2): 203–17. DOI: 10.1016/j.cnur.2020.10.012
3. Ротарь O.П., Колесова Е.П., Могучая Е.В., Бояринова М.А., Хромова Н.В., Алиева А.С., Васильева Е.Ю., Беляева О.Д., Баженова Е.А., Баранова Е.И., Черепанова Н.А., Дупляков Д.В., Либис P.А., Басырова И.Р., Лопина Е.А., Душина А.Г., Солнцев В.Н., Костарева А.А., Конради А.О., Шляхто Е.В. Генетические маркеры метаболического синдрома в российской популяции (по материалам исследования ЭССЕ-РФ). Артериальная гипертензия. 2019; 25 (5): 467–77. https://doi.org/10.18705/1607-419X-2019-25-5-467-477 [Rotar O.P., Kolesova E.P., Moguchaya E.V., Boyarinova M.A., Khromova N.V., Alieva A.S., Vasilieva E.Yu., Belyaeva O.D., Bazhenova E.A., Baranova E.I., Cherepanova N.A., Duplyakov D.V., Libis R.A., Basyrova I.R., Lopina E.A., Dushina A.G., Solntsev V.N., Kostareva A.A., Konradi A.O., Shlyakhto E.V. Genetic markers of metabolic syndrome in the Russian population (based on the ESSE-RF study). Arterial Hypertension. 2019; 25 (5): 467–77 (in Russian)].
4. Saklayen M.G. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20 (2): 12. Published 2018 Feb 26. DOI: 10.1007/s11906-018-0812-z
5. Lemieux I., Després J.P. Metabolic Syndrome: Past, Present and Future. Nutrients. 2020; 12 (11): 3501. Published 2020 Nov 14. DOI: 10.3390/nu12113501
6. Ghadge A.A., Khaire A.A. Leptin as a predictive marker for metabolic syndrome. Cytokine. 2019; 121: 154735. DOI: 10.1016/j.cyto.2019.154735
7. Вербовой А.Ф., Вербовая Н.И., Долгих Ю.А. Ожирение – основа метаболического синдрома. Ожирение и метаболизм. 2021; 18 (2): 142–9. https://doi.org/10.14341/omet12707 [Verbovoy A.F., Verbovaya N.I., Dolgikh Yu.A. Obesity – the basis of metabolic syndrome. Obesity and Metabolism. 2021; 18 (2): 142–9 (in Russian)].
8. Erratum: Pandemic of Vitamin D Deficiency: Cardiometabolic Concern or Skeletal Biochemical Abnormality. Indian J. Endocrinol Metab. 2019; 23 (3): 386. DOI: 10.4103/2230-8210.263698
9. Ferreira P.P., Cangussu L., Bueloni-Dias F.N. et al. Vitamin D supplementation improves the metabolic syndrome risk profile in postmenopausal women. Climacteric. 2020; 23 (1): 24–31. DOI: 10.1080/13697137.2019.1611761
10. Schmitt E.B., Nahas-Neto J., Bueloni-Dias F., Poloni P.F., Orsatti C.L., Petri Nahas E.A. Vitamin D deficiency is associated with metabolic syndrome in postmenopausal women. Maturitas. 2018; 107: 97–102. DOI: 10.1016/j.maturitas.2017.10.011
11. Ghaderi A., Banafshe H.R., Motmaen M., Rasouli-Azad M., Bahmani F., Asemi Z. Clinical trial of the effects of vitamin D supplementation on psychological symptoms and metabolic profiles in maintenance methadone treatment patients. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 79 (Pt B): 84–9. DOI: 10.1016/j.pnpbp.2017.06.016
12. Vigna L., Speciani M.C., Tirelli A.S. et al. Vitamin D and Metabolic Syndrome in Working Age Subjects from an Obesity Clinic. Nutrients. 2023; 15 (20): 4354. Published 2023 Oct 12. DOI: 10.3390/nu15204354
13. Faraji S., Alizadeh M. Mechanistic Effects of Vitamin D Supplementation on Metabolic Syndrome Components in Patients with or without Vitamin D Deficiency. J. Obes Metab Syndr. 2020; 29 (4): 270–80. DOI: 10.7570/jomes20003
14. Lemieux P., Weisnagel S.J., Caron A.Z. et al. Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial. Eur. J. Endocrinol. 2019; 181 (3): 287–99. DOI: 10.1530/EJE-19-0156
15. Barbarawi M., Zayed Y., Barbarawi O. et al. Effect of Vitamin D Supplementation on the Incidence of Diabetes Mellitus. J. Clin. Endocrinol Metab. 2020; 105 (8): dgaa335. DOI: 10.1210/clinem/dgaa335
16. Talari H.R., Najafi V., Raygan F. et al. Long-term vitamin D and high-dose n-3 fatty acids’ supplementation improve markers of cardiometabolic risk in type 2 diabetic patients with CHD [published correction appears in Br. J. Nutr. 2019; 122 (6): 719. DOI: 10.1017/S0007114519001971.]. Br. J. Nutr. 2019; 122 (4): 423–30. DOI: 10.1017/S0007114519001132
17. Ghaderi A., Banafshe H.R., Motmaen M., Rasouli-Azad M., Bahmani F., Asemi Z. Clinical trial of the effects of vitamin D supplementation on psychological symptoms and metabolic profiles in maintenance methadone treatment patients. Prog Neuropsychopharmacol Biol. Psychiatry. 2017; 79 (Pt B): 84–9. DOI: 10.1016/j.pnpbp.2017.06.016
18. Jamilian M., Samimi M., Ebrahimi F.A. et al. The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes. J. Clin. Lipidol. 2017; 11 (2): 459–68. DOI: 10.1016/j.jacl.2017.01.011
19. Huang C.Y., Chang H.H., Lu C.W., Tseng F.Y., Lee L.T., Huang K.C. Vitamin D status and risk of metabolic syndrome among non-diabetic young adults. Clin Nutr. 2015; 34 (3): 484–9. DOI: 10.1016/j.clnu.2014.05.010
20. Lee S.J., Lee E.Y., Lee J.H. et al. Associations of serum 25-hydroxyvitamin D with metabolic syndrome and its components in elderly men and women: the Korean Urban Rural Elderly cohort study [published correction appears in BMC Geriatr. 2019; 19 (1): 131. DOI: 10.1186/s12877-019-1150-y.]. BMC Geriatr. 2019; 19 (1): 102. Published 2019 Apr 11. DOI: 10.1186/s12877-019-1118-y
21. Zhu W., Heil D.P. Associations of vitamin D status with markers of metabolic health: A community-based study in Shanghai, China. Diabetes Metab Syndr. 2018; 12 (5): 727–32. DOI: 10.1016/j.dsx.2018.04.010
22. Barbalho S.M., Tofano R.J., de Campos A.L. et al. Association between vitamin D status and metabolic syndrome risk factors. Diabetes Metab Syndr. 2018; 12 (4): 501–7. DOI: 10.1016/j.dsx.2018.03.011
23. Perna S. Is Vitamin D Supplementation Useful for Weight Loss Programs? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicina (Kaunas). 2019; 55 (7): 368. Published 2019 Jul 12. DOI: 10.3390/medicina55070368
24. Lotfi-Dizaji L., Mahboob S., Aliashrafi S., Vaghef-Mehrabany E., Ebrahimi-Mameghani M., Morovati A. Effect of vitamin D supplementation along with weight loss diet on meta-inflammation and fat mass in obese subjects with vitamin D deficiency: A double-blind placebo-controlled randomized clinical trial. Clin Endocrinol (Oxf). 2019; 90 (1): 94–101. DOI: 10.1111/cen.13861
25. Duan L., Han L., Liu Q., Zhao Y., Wang L., Wang Y. Effects of Vitamin D Supplementation on General and Central Obesity: Results from 20 Randomized Controlled Trials Involving Apparently Healthy Populations. Ann Nutr Metab. 2020; 76 (3): 153–64. DOI: 10.1159/000507418
26. Brzeziński M., Jankowska A., Słomińska-Frączek M. et al. Long-Term Effects of Vitamin D Supplementation in Obese Children During Integrated Weight-Loss Programme-A Double Blind Randomized Placebo-Controlled Trial. Nutrients. 2020; 12 (4): 1093. Published 2020 Apr 15. DOI: 10.3390/nu12041093
27. Mazidi M., Rezaie P., Banach M. Effect of magnesium supplements on serum C-reactive protein: a systematic review and meta-analysis. Arch Med Sci. 2018; 14 (4): 707–16. DOI: 10.5114/aoms.2018.75719
28. Razzaque .MS. Magnesium: Are We Consuming Enough? Nutrients. 2018; 10 (12): 1863. Published 2018 Dec 2. DOI: 10.3390/nu10121863
29. Rondanelli M., Faliva M.A., Gasparri C. et al. Micronutrients Dietary Supplementation Advices for Celiac Patients on Long-Term Gluten-Free Diet with Good Compliance: A Review. Medicina (Kaunas). 2019; 55 (7): 337. Published 2019 Jul 3. DOI: 10.3390/medicina55070337
30. DiNicolantonio J.J., O’Keefe J.H., Wilson W. Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis [published correction appears in Open Heart. 2018; 5 (1): e000668corr1. DOI: 10.1136/openhrt-2017-000668corr1.]. Open Heart. 2018; 5 (1): e000668. Published 2018 Jan 13. DOI: 10.1136/openhrt-2017-000668
31. Chrysant S.G. Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias. Expert Rev. Cardiovasc. 2019; 17: 345–51.
32. Maguire D., Ross D.P., Talwar D. et al. Low serum magnesium and 1-year mortality in alcohol withdrawal syndrome. Eur. J. Clin. Invest. 2019; 49 (9): e13152. DOI: 10.1111/eci.13152
33. Nielsen F.H. Magnesium deficiency and increased inflammation: current perspectives. J. Inflamm Res. 2018; 11: 25–34. Published 2018 Jan 18. DOI: 10.2147/JIR.S136742
34. Jiang S., Ma X., Li M. et al. Association between dietary mineral nutrient intake, body mass index, and waist circumference in U.S. adults using quantile regression analysis NHANES 2007–2014. PeerJ. 2020; 8: e9127. Published 2020 May 4. DOI: 10.7717/peerj.9127
35. Castellanos-Gutiérrez A., Sánchez-Pimienta T.G., Carriquiry A., da Costa T.H.M., Ariza A.C. Higher dietary magnesium intake is associated with lower body mass index, waist circumference and serum glucose in Mexican adults. Nutr J. 2018; 17 (1): 114. Published 2018 Dec 5. DOI: 10.1186/s12937-018-0422-2
36. Maguire D., Talwar D., Shiels P.G., McMillan D. The role of thiamine dependent enzymes in obesity and obesity related chronic disease states: A systematic review. Clin Nutr ESPEN. 2018; 25: 8–17. DOI: 10.1016/j.clnesp.2018.02.007
37. Matias P., Ávila G., Ferreira A.C., Laranjinha I., Ferreira A. Hypomagnesemia: a potential underlooked cause of persistent vitamin D deficiency in chronic kidney disease. Clin Kidney J. 2023; 16 (11): 1776–85. Published 2023 Jun 1. DOI: 10.1093/ckj/sfad123
38. Piuri G., Zocchi M., Della Porta M. et al. Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes. Nutrients. 2021; 13 (2): 320. Published 2021 Jan 22. DOI: 10.3390/nu13020320
39. Yang N., He L., Li Y. et al. Reduced Insulin Resistance Partly Mediated the Association of High Dietary Magnesium Intake with Less Metabolic Syndrome in a Large Chinese Population. Diabetes Metab Syndr Obes. 2020; 13: 2541–50. Published 2020 Jul 17. DOI: 10.2147/DMSO.S257884
40. Veronese N., Demurtas J., Pesolillo G. et al. Magnesium and health outcomes: an umbrella review of systematic reviews and meta-analyses of observational and intervention studies. Eur. J. Nutr. 2020; 59 (1): 263–72. DOI: 10.1007/s00394-019-01905-w
41. Wang Y., Wei J., Zeng C. et al. Association between serum magnesium concentration and metabolic syndrome, diabetes, hypertension and hyperuricaemia in knee osteoarthritis: a cross-sectional study in Hunan Province, China. BMJ Open. 2018; 8 (9): e019159. Published 2018 Sep 10. DOI: 10.1136/bmjopen-2017-019159
42. Han D., Fang X., Su D. et al. Dietary Calcium Intake and the Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis. Sci Rep. 2019; 9 (1): 19046. Published 2019 Dec 13. DOI: 10.1038/s41598-019-55507-x
43. ELDerawi W.A., Naser I.A., Taleb M.H., Abutair A.S. The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients. Nutrients. 2018; 11 (1): 44. Published 2018 Dec 26. DOI: 10.3390/nu11010044
44. Banjanin N., Belojevic G. Changes of Blood Pressure and Hemodynamic Parameters after Oral Magnesium Supplementation in Patients with Essential Hypertension-An Intervention Study. Nutrients. 2018; 10 (5): 581. Published 2018 May 8. DOI: 10.3390/nu10050581
45. Жуков А.Ю., Ворслов Л.О., Давидян О.В. Омега-3 индекс: современный взгляд и место в клинической практике. Вопросы диетологии. 2017; 7 (2): 69–74. DOI: 10.20953/2224-5448-2017-2-69-74 [Zhukov A.Yu., Vorslov L.O., Davidyan O.V. Omega-3 index: a modern view and its place in clinical practice. Nutrition Issues (Voprosy Dietologii). 2017; 7 (2): 69–74. DOI: 10.20953/2224-5448-2017-2-69-74 (in Russian)].
46. Schuchardt J.P., Beinhorn P., Hu X.F. et al. Omega-3 world map: 2024 update. Prog Lipid Res. 2024; 95: 101286. DOI: 10.1016/j.plipres.2024.101286
47. Djuricic I., Calder P.C. Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021. Nutrients. 2021; 13 (7): 2421. Published 2021 Jul 15. DOI: 10.3390/nu13072421
48. Walker R.E., Jackson K.H., Tintle N.L. et al. Predicting the effects of supplemental EPA and DHA on the omega-3 index. Am. J. Clin. Nutr. 2019; 110 (4): 1034–40. DOI: 10.1093/ajcn/nqz161
49. Musazadeh V., Tandorost А., Zarezadeh M., Jafarzadeh J., Ghavami Z., Jamilian P., Ostadrahimi A. Can omega-3 fatty acids and vitamin E co-supplementation affect obesity indices? A meta-analysis. Int. J. Vitam. Nutr. Res. 2023; 93 (5): 471–80. https://doi.org/10.1024/0300-9831/a000757
50. Быстрова В.И., Шрайнер Е.В., Лифшиц Г.И., Покушалов Е.А., Кудлай Д.А. ω-3 полиненасыщенные жирные кислоты: эффекты, биодоступность, применение во время беременности. Вопросы гинекологии, акушерства и перинатологии. 2025; 24 (3): 132–41. DOI: 10.20953/1726-1678-2025-3-132-141 [Bystrova V.I., Shriner E.V., Lifshits G.I., Pokushalov E.A., Kudlay D.A. omega-3 polyunsaturated fatty acids: effects, bioavailability, use during pregnancy. Issues of gynecology, obstetrics and perinatology. 2025; 24 (3): 132–41. DOI: 10.20953/1726-1678-2025-3-132-141 (in Russian)].
51. Лифшиц Г.И., Кох Н.В., Киреева В.В., Апарцин К.А. Некоторые молекулярно-генетические механизмы формирования ожирения и метаболического синдрома. Фармакогенетика и фармакогеномика. 2017; 1: 5–9. [Lifshits G.I., Koh N.V., Kireeva V.V., Apartsin K.A. Some molecular genetic mechanisms of obesity and metabolic syndrome formation. Pharmacogenetics and pharmacogenomics. 2017; 1: 5–9 (in Russian)].